213 related articles for article (PubMed ID: 34091713)
1. A bicentric retrospective analysis of clinical utility of
Salavati A; Gencturk M; Koksel Y; Schik AN; Carroll PR; Feng FY; Rowe SP; Lawhn-Heath C; Hope TA; Froelich JW
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4463-4471. PubMed ID: 34091713
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis.
Subiela JD; Gomis Sellés E; Maldonado A; Lopez Campos F; Aumatell Ovide J; Ajuria Illarramendi O; González-Padilla DA; Gajate P; Ortega Polledo LE; Alonso Y Gregorio S; Guerrero-Ramos F; Gómez Dos Santos V; Rodríguez-Patrón R; Calais J; Kishan AU; Burgos Revilla FJ; Couñago F
Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e676-e688. PubMed ID: 37802722
[TBL] [Abstract][Full Text] [Related]
4.
Ilhan H; Kroenke M; Wurzer A; Unterrainer M; Heck M; Belka C; Knorr K; Langbein T; Rauscher I; Schmidt-Hegemann NS; Schiller K; Bartenstein P; Wester HJ; Eiber M
J Nucl Med; 2022 Aug; 63(8):1208-1214. PubMed ID: 35273094
[TBL] [Abstract][Full Text] [Related]
5. Predicting
Lee KH; Mena E; Shih J; Lindenberg L; Wood BJ; Pinto PA; Patel KR; Citrin DE; Choyke PL; Turkbey B
Acad Radiol; 2024 Apr; 31(4):1419-1428. PubMed ID: 37775447
[TBL] [Abstract][Full Text] [Related]
6. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
7. [
Ferrari C; Mammucci P; Lavelli V; Pisani AR; Nappi AG; Rubini D; Sardaro A; Rubini G
Tomography; 2022 Nov; 8(6):2709-2722. PubMed ID: 36412685
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
Kim EH; Siegel BA; Teoh EJ; Andriole GL;
Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment.
Chen B; Bathala TK; Xu G; Teyateeti A; Chapin BF; Tang C; Tu SM; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 May; 45(5):349-355. PubMed ID: 31977495
[TBL] [Abstract][Full Text] [Related]
10. Effect of hormonal therapy on
Bulbul JE; Hashem A; Grybowski D; Joyce C; Rashad E; Gabriel MS; Wagner RH; Savir-Baruch B
Urol Oncol; 2022 Aug; 40(8):379.e9-379.e16. PubMed ID: 35738974
[TBL] [Abstract][Full Text] [Related]
11.
Armstrong JM; Martin CR; Dechet C; Morton K; Evans D; Ambrose J; Maughan BL; O'Neil B; Lowrance W
Urol Oncol; 2020 Jul; 38(7):636.e1-636.e6. PubMed ID: 32317221
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
13. The use of
Raveenthiran S; Yaxley J; Gianduzzo T; Kua B; McEwan L; Wong D; Tsang G; MacKean J
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):385-390. PubMed ID: 31363165
[TBL] [Abstract][Full Text] [Related]
14. PSMA-targeted Radiotracers versus
Tan N; Oyoyo U; Bavadian N; Ferguson N; Mukkamala A; Calais J; Davenport MS
Radiology; 2020 Jul; 296(1):44-55. PubMed ID: 32396045
[TBL] [Abstract][Full Text] [Related]
15. Utility of
Wang Y; Chow DZ; Ebert E; Tajmir S; Scott JA; Palmer EL
AJR Am J Roentgenol; 2020 Oct; 215(4):997-1001. PubMed ID: 32569513
[No Abstract] [Full Text] [Related]
16. 18F-Fluciclovine PET/CT Detection of Recurrent Prostate Carcinoma in Patients With Serum PSA ≤ 1 ng/mL After Definitive Primary Treatment.
England JR; Paluch J; Ballas LK; Jadvar H
Clin Nucl Med; 2019 Mar; 44(3):e128-e132. PubMed ID: 30589673
[TBL] [Abstract][Full Text] [Related]
17. Detection of Recurrent Prostate Cancer With
Selnæs KM; Krüger-Stokke B; Elschot M; Johansen H; Steen PA; Langørgen S; Aksnessæther BY; Indrebø G; Sjøbakk TAE; Tessem MB; Moestue SA; Knobel H; Tandstad T; Bertilsson H; Solberg A; Bathen TF
Front Oncol; 2020; 10():582092. PubMed ID: 33425735
[TBL] [Abstract][Full Text] [Related]
18. Effect of
Scarsbrook AF; Bottomley D; Teoh EJ; Bradley KM; Payne H; Afaq A; Bomanji J; van As N; Chua S; Hoskin P; Chambers A; Cook GJ; Warbey VS; Han S; Leung HY; Chau A; Miller MP; Gleeson FV;
Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):316-324. PubMed ID: 32068113
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level ≤0.5 ng/mL.
Teyateeti A; Khan B; Teyateeti A; Chen B; Bridhikitti J; Pan T; Peng W; Macapinlac HA; Lu Y
Nucl Med Commun; 2020 Sep; 41(9):906-915. PubMed ID: 32796479
[TBL] [Abstract][Full Text] [Related]
20. Prospective Evaluation of
Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A
J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216
[No Abstract] [Full Text] [Related]
[Next] [New Search]
